Knowledge Graph
Graph explorer
Search resolved entities, walk their edges, and read the sentence behind every one.
Entities25 of 207,987
- large language modeltechnology1,047 mentions
- robotic manipulationmarket829 mentions
- artificial intelligencetechnology739 mentions
- reinforcement learningtechnology491 mentions
- density-functional theorytechnology386 mentions
- Transformertechnology372 mentions
- vision-language-action modeltechnology353 mentions
- agentic AItechnology353 mentions
- U.S. Food and Drug Administrationorganization320 mentions
- Vision-Language Modeltechnology320 mentions
- Microsoftorganization291 mentions
- Googleorganization276 mentions
- NVIDIAorganization264 mentions
- Model Context Protocoltechnology232 mentions
- machine learningtechnology204 mentions
- MarketsandMarketsorganization199 mentions
- Claudeproduct192 mentions
- AI agenttechnology188 mentions
- ChatGPTproduct178 mentions
- Anthropicorganization177 mentions
- integrated sensing and communicationtechnology176 mentions
- Amazon Web Services, Inc.organization174 mentions
- OpenAIorganization172 mentions
- diffusion modeltechnology169 mentions
- IBMorganization163 mentions
Entity
Theravance Biopharma, Inc.
organization2 mentionslast seen Sep 23, 2026
Biopharmaceutical company acquired by Zymeworks on September 23, 2026.
Relationships 5
- Zymeworks Inc.acquiresTheravance Biopharma, Inc.99% confidence2 sources
- Zymeworks Inc.ownsTheravance Biopharma, Inc.99% confidence1 source
- Theravance Biopharma, Inc.employsRick E Winningham90% confidence1 source
- Theravance Biopharma, Inc.employsSusannah Gray85% confidence1 source
- Theravance Biopharma, Inc.developsampreloxetine80% confidence1 source
Relationship
Zymeworks Inc.acquiresTheravance Biopharma, Inc.
99% confidence2 supporting mentionsfrom Sep 23, 2026
Either name opens that entity’s relationships.
Sources 2
- filingSEC EDGARSep 23, 2026Theravance Biopharma, Inc. 8-K: Item 1.01: Entry into a Material Definitive Agreement; Item 2.01: Completion of Acquisition or Disposition of Assets; Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing; Item 3.03: Material Modifications to Rights of Security Holders; Item 5.01: Changes in Control of Registrant; Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers; Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year; Item 8.01: Other Events; Item 9.01: Financial Statements and Exhibits
the completion on September 23, 2026 of the transactions contemplated by that certain Agreement and Plan of Merger...by and among Theravance Biopharma, Inc....Zymeworks Inc.,...Merger Sub merged with and into the Company...with the Company surviving the Merger as a wholly owned subsidiary of Parent
- filingSEC EDGARSep 23, 2026Zymeworks Inc. 8-K: Item 1.01: Entry into a Material Definitive Agreement; Item 2.01: Completion of Acquisition or Disposition of Assets; Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant; Item 7.01: Regulation FD Disclosure; Item 9.01: Financial Statements and Exhibits
Zymeworks Inc. completed the previously announced merger contemplated pursuant to the terms and conditions of the Agreement and Plan of Merger, dated June 28, 2026, by and among Zymeworks, Theravance Biopharma, Inc.